MARIANNE: Impact on current treatment ofhuman epidermal growth factor receptor 2-positive metastatic breast cancer and implications for the future

Journal of Clinical Oncology

Volumn 35, Issue 2, 2017, Pages 127-130

  Jhaveri, Komal ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; DOCETAXEL; LAPATINIB; NERATINIB; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TUCATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MAYTANSINE; MONOCLONAL ANTIBODY; TAXOID;

ADVERSE DRUG REACTION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL EFFECTIVENESS; HEALTH CARE QUALITY; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; METASTATIC BREAST CANCER; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANALOGS AND DERIVATIVES; BREAST TUMOR;

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; HUMANS; MAYTANSINE; RECEPTOR, ERBB-2; TAXOIDS; TRASTUZUMAB;

EID: 85009769686     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.70.2712     Document Type: Review

References (34)

1. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001.
2. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2- positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006.
3. Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012.
4. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791, 2012.
5. Giordano SH, Temin S, Kirshner JJ, et al: Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32: 2078-2099, 2014.
6. Hurvitz SA, Dirix L, Kocsis J, et al: Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31: 1157-1163, 2013.
7. Miller KD, Diéras V, Harbeck N, et al: Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol 32: 1437-1444, 2014.
8. Perez EA, Barrios C, Eiermann W, et al: Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Primary results from the phase III MARIANNE study. J Clin Oncol 35:141-148, 2017.
9. Gianni L, Romieu GH, Lichinitser M, et al: AVEREL: A randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 31:1719-1725, 2013.
10. Hurvitz SA, Andre F, Jiang Z, et al: Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): A phase 3, randomised, double-blind, multicentre trial. Lancet Oncol 16:816-829, 2015.
11. Valero V, Forbes J, Pegram MD, et al: Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): Two highly active therapeutic regimens. J Clin Oncol 29:149-156, 2011.
12. Andersson M, Lidbrink E, Bjerre K, et al: Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as firstline therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA study. J Clin Oncol 29:264-271, 2011.
13. Swain SM, Baselga J, Kim S-B, et al: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724-734, 2015.
14. Hudis CA: Trastuzumab-Mechanism of action and use in clinical practice. N Engl J Med 357:39-51, 2007.
15. Lewis Phillips GD, Li G, Dugger DL, et al: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290, 2008.
16. Hurvitz SA, Martin M, Symmans WF, et al: Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) 1 pertuzumab (P) vs docetaxel 1 carboplatin 1 trastuzumab 1 P (TCHP) treatment in patients with HER2-positive (HER21) early breast cancer (EBC) (KRISTINE). J Clin Oncol 34, 2016 (suppl; abstr 500).
17. Burris HA III, Rugo HS, Vukelja SJ, et al: Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398-405, 2011.
18. Scaltriti M, Nuciforo P, Bradbury I, et al: High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin Cancer Res 21: 569-576, 2015.
19. Perez EA, Hurvitz SA, Amler LC, et al: Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: A randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Breast Cancer Res 16:R50, 2014.
20. Baselga J, Cortés J, Im SA, et al: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 32: 3753-3761, 2014.
21. Barok M, Joensuu H, Isola J: Trastuzumab emtansine: Mechanisms of action and drug resistance. Breast Cancer Res 16:209, 2014.
22. Krop I, Winer EP: Trastuzumab emtansine: A novel antibody-drug conjugate for HER2-positive breast cancer. Clin Cancer Res 20:15-20, 2014.
23. Diéras V, Harbeck N, Budd GT, et al: Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: An integrated safety analysis. J Clin Oncol 32:2750-2757, 2014.
24. Krop IE, Kim SB, Gonźalez-Martín A, et al: Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomised, open-label, phase 3 trial. Lancet Oncol 15: 689-699, 2014.
25. Dang C, Iyengar N, Datko F, et al: Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 33: 442-447, 2015.
26. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: Breast cancer version 2.2016. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#site.
27. O'Shaughnessy J, Osborne C, Pippen JE, et al: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364:205-214, 2011.
28. O'Shaughnessy J, Schwartzberg L, Danso MA, et al: Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 32:3840-3847, 2014.
29. Saura C, Garcia-Saenz JA, Xu B, et al: Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 32:3626-3633, 2014.
30. Borges VF, Ferrario C, Aucoin N, et al: Efficacy results of a phase 1b study of ont-380, a CNS-penetrant TKI, in combination with T-DM1 in HER21 metastatic breast cancer (MBC), including patients (pts) with brain metastases. J Clin Oncol 34, 2016 (suppl; abstr 513).
31. Jhaveri K, Esteva FJ: Pertuzumab in the treatment of HER21 breast cancer. J Natl Compr Canc Netw 12:591-598, 2014.
32. Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127, 2004.
33. Baselga J, Lewis Phillips GD, Verma S, et al: Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer. Clin Cancer Res 22:3755-3763, 2016.
34. Kim SB, Wildiers H, Krop IE, et al: Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. Int J Cancer 139:2336-2342, 2016.